We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$209M
AUM Growth
+$36.3M
Cap. Flow
+$30.7M
Cap. Flow %
14.69%
Top 10 Hldgs %
52.12%
Holding
81
New
22
Increased
17
Reduced
10
Closed
28

Top Buys

Rank Stock Value
1
OLED icon
Universal Display
OLED
+$12.7M
2
TVTX icon
Travere Therapeutics
TVTX
+$7.39M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$7.03M
4
CEMP
Cempra, Inc.
CEMP
+$6.54M
5
IMMU
Immunomedics Inc
IMMU
+$6.29M

Top Sells

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$4.3M
2
BEAT
BioTelemetry, Inc.
BEAT
+$3.79M
3
EXEL icon
Exelixis
EXEL
+$3.76M
4
WBMD
WebMD Health Corp.
WBMD
+$3.17M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.09M

Sector Composition

Rank Sector Weight
1 Healthcare 73.49%
2 Miscellaneous 17.47%
3 Technology 7.48%
4 Consumer Discretionary 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIN
51
DELISTED
Kindred Biosciences, Inc.
KIN
$170K 0.08%
50,000
– –
NBSE
52
PUT
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$61K 0.03%
+25
New +$38.4K
ABEO icon
53
Abeona Therapeutics
ABEO
$319M
– –
-4,454
Closed -$451K
AGEN
54
Agenus
AGEN
$333M
– –
-25,985
Closed -$2.35M
ARWR icon
55
PUT
Arrowhead Research
ARWR
$9.46B
– –
-50,000
Closed -$288K
AUPH icon
56
Aurinia Pharmaceuticals
AUPH
$2.25B
– –
-377,427
Closed -$1.07M
AXDX
57
PUT
DELISTED
Accelerate Diagnostics
AXDX
– –
-1,500
Closed -$243K
BCRX icon
58
BioCryst Pharmaceuticals
BCRX
$2.25B
– –
-271,399
Closed -$3.09M
CDTX
59
DELISTED
Cidara Therapeutics
CDTX
– –
-2,956
Closed -$752K
EWA icon
60
PUT
iShares MSCI Australia ETF
EWA
$1.27B
– –
-50,000
Closed -$896K
IWM icon
61
PUT
iShares Russell 2000 ETF
IWM
$76.3B
– –
-70,000
Closed -$7.64M
LRMR icon
62
Larimar Therapeutics
LRMR
$400M
– –
-4,293
Closed -$1.65M
LXRX icon
63
Lexicon Pharmaceuticals
LXRX
$890M
– –
-400,000
Closed -$4.3M
OCGN icon
64
Ocugen
OCGN
$343M
– –
-2,054
Closed -$491K
SRPT icon
65
Sarepta Therapeutics
SRPT
$2.12B
– –
-31,744
Closed -$1.03M
VIVS
66
PUT
VivoSim Labs
VIVS
$3.46M
– –
-500
Closed -$322K
TAST
67
DELISTED
Carrols Restaurant Group, Inc.
TAST
– –
-128,643
Closed -$1.53M
EIGR
68
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,822
Closed -$861K
AGRX
69
DELISTED
Agile Therapeutics
AGRX
– –
-71
Closed -$952K
SIOX
70
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-17,500
Closed -$1.81M
ALBO
71
DELISTED
Albireo Pharma Inc
ALBO
– –
-84,961
Closed -$1.12M
SRNE
72
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-300,000
Closed -$2.52M
CLVS
73
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-15,000
Closed -$1.38M
AGTC
74
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-221,138
Closed -$2.91M
EPZM
75
DELISTED
Epizyme, Inc
EPZM
– –
-140,000
Closed -$1.8M
1 2
3
4

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q4 2015 Portfolio in Review

As of Q4 2015, Acuta Capital Partners held 81 positions worth $209M, up 21% from $173M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Acuta Capital Partners deployed $30.7M of net new capital in Q4 2015, opening 22 new positions and adding to 17 existing holdings. Its largest new stake was Universal Display: 287,397 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 80% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was BioTelemetry, Inc., an estimated $3.79M trimmed.

  • Acuta Capital Partners's largest Q4 2015 buy was Universal Display: 287,397 shares worth $15.6M.
  • Acuta Capital Partners added most to Cempra, Inc. in Q4 2015, an estimated $6.54M increase.
  • Acuta Capital Partners's biggest Q4 2015 reduction was BioTelemetry, Inc., cutting an estimated $3.79M.
  • Acuta Capital Partners fully exited Lexicon Pharmaceuticals in Q4 2015, selling an estimated $4.3M.
  • Acuta Capital Partners's ten largest holdings make up 52% of its $209M portfolio in Q4 2015.
  • Acuta Capital Partners opened 22 new positions and closed 28 in Q4 2015.
  • Acuta Capital Partners's portfolio value rose 21% quarter-over-quarter to $209M.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.